Utility of PET/CT in patients with stage I-III melanoma

被引：9
|
作者：
Aviles Izquierdo, J. A. [1 ]
Molina Lopez, I. [1 ]
Sobrini Morillo, P. [2 ]
Marquez Rodas, I. [3 ,4 ]
Mercader Cidoncha, E. [5 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Serv Dermatol, Calle Dr Esquerdo 46, Madrid 28007, Spain
[2] Univ Complutense Madrid, Fac Med, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Serv Oncol Med, Madrid, Spain
[4] Ciberonc, Madrid, Spain
[5] Hosp Gen Univ Gregorio Maranon, Serv Cirugia Gen, Madrid, Spain
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2020年 / 22卷 / 08期
关键词：
Melanoma; Diagnosis; Staging; PET; CT; Sentinel lymph node biopsy; Complete lymph node dissection; Skin metastases; F-18-FDG PET/CT; TOMOGRAPHY; CT;
D O I：
10.1007/s12094-019-02252-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose To study the utility of positron emission tomography with computerized tomography (PET/CT) in patients with a stage I-III melanoma. Patients and methods PET/CT findings from all patients with a stage I-III melanoma attended at our hospital from September 2011 to November 2015 were reviewed. Results Data from 83 patients with a stage I-III melanoma, 39 patients with a positive sentinel lymph node biopsy (SLNB) and 35 patients with locoregional recurrences were analyzed. Sensitivity of PET/CT in clinical stage I-III patients was 5%, with a 14% of false positives. In patients with a positive SLNB, PET/CT previous to complete lymph node dissection had a 23% of false negatives. In patients with clinical locoregional recurrences, PET/CT findings revealed asymptomatic visceral distant metastasis in 25.7%. Conclusions PET/CT has a significant rate of false positive and negative results in patients with a stage I-III melanoma. Utility in patients with nodal locoregional recurrences seems higher than in patients with skin metastases.
引用
收藏
页码：1414 / 1417
页数：4
相关论文
共 50 条
  • [21] Radiotherapy for Patients with Stage I-III NSCLC in a geriatric Cllective - A monocentric Analysis
    Alt, N.
    Muster, J.
    Rieken, S.
    Leu, M.
    Habermann, F. -N.
    Droege, L.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S147 - S148
  • [22] Sociodemographic predictors of surgery refusal in patients with stage I-III colon cancer
    Lu, Pamela W.
    Fields, Adam C.
    Yoo, James
    Irani, Jennifer
    Goldberg, Joel E.
    Bleday, Ronald
    Melnitchouk, Nelya
    JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (08) : 1306 - 1313
  • [23] Effect of glucocorticoid use on survival in patients with stage I-III breast cancer
    Lin, Ching-Hung
    Chuang, Po-Ya
    You, San-Lin
    Chiang, Chun-Ju
    Huang, Chiun-Sheng
    Wang, Ming-Yang
    Chao, Ming
    Lu, Yen-Shen
    Cheng, Ann-Lii
    Tang, Chao-Hsiun
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 225 - 234
  • [24] Stage I-III disease: surgical and systemic options
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2022, 15 (SUPPL 8) : S149 - S151
  • [25] False Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma
    Nijhuis, A.
    Dieng, M.
    Lord, S.
    Dalton, J.
    Menzies, A.
    Turner, R.
    Allen, J.
    Saw, R.
    Nieweg, O.
    Thompson, J.
    Morton, R.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S39 - S39
  • [26] Clinical relevance of PET scan in stage III & IV melanoma patients
    Stas, M
    Stroobants, S
    Dupont, P
    Gysen, M
    Van Hoe, L
    Mulier, S
    Garmyn, M
    De Wever, I
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S370 - S370
  • [27] Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study
    Kaumanns, Anna
    Konig, David
    Hojski, Aljaz
    Cattaneo, Marco
    Chirindel, Alin
    Wiese, Mark
    Tamm, Michael
    Lardinois, Didier
    Rothschild, Sacha I.
    LUNG CANCER, 2022, 173 : 14 - 20
  • [28] Quantification of tumor heterogeneity using textural features analysis of PET and CT images provides complementary prognostic value in stage I-III NSCLC
    Desseroit, Marie-Charlotte
    Majdoub, Mohamed
    Tixier, Florent
    Visvikis, Dimitris
    Le Rest, Catherine Cheze
    Hatt, Mathieu
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [29] Change in treatment as result of FDG-PET and CT in clinically stage III melanoma patients: A prospective study in 221 patients
    Bastiaannet, E.
    Wobbes, T.
    Meijer, S.
    Hoekstra, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] The prognostic value of CXC subfamily ligands in stage I-III patients with colorectal cancer
    Li, Xiangde
    Zhong, Qiulu
    Luo, Danjing
    Du, Qinghua
    Liu, Wenqi
    PLOS ONE, 2019, 14 (04):
12345